Study | Treatment | No of patients | Incidence of neutropenia | Grade of neutropenia | Median time to neutropenia | Median duration of neutropenia | Treatment | Comments |
---|---|---|---|---|---|---|---|---|
Coles AJ et al., 2012 [16] | 1rst year of infusion (24 mg/d) | 1/161 | 0,60% | NA | NA | NA | NA | Febrile neutropenia |
Willis et al, 2016 [9] | NA | 1/100 | 1% | NA | Median time to development of acquired autoimmune manifestations was 995 days following first treatment. | NA | NA | None |
Gaitán MI et al., 2017 [5] | 1rst year of infusion (12 mg/d) | 1 | case report | IV | 4 weeks | 3 days | Granulocyte-stimulating factor (300 mg/day for 72 h) | Responsive to 1 cycle of G-SCF, but developed HSV-1 infection that needed advanced antibiotics |
Gaitán MI et al., 2017 [5] | 1rst year of infusion (12 mg/d) | 1 | case report | IV-III (two episodes) | 6 and 8 weeks (two episodes) | 3 | Granulocyte-stimulating factor (300 mg/day for 72 h) | Responsive to 2 cycles of G-SCF. Febrile neutropenia andsinusitis that needed iv antibiotics |
Baker D et al., 2017 [4] | 1rst year of infusion (12 mg/d) | 127/811 | 15,70% | I-II | NA | NA | Data from CARE-MS I and CARE-MS II. | |
Baker D et al., 2017 [4] | 1rst year of infusion (12 mg/d) | 5/811 | 0,60% | III-IV | NA | NA | 2 patients developed agranulocytosis,the first teated with PLEX and the other with lenograstim | Data from CARE-MS I and CARE-MS II. |
Baker D et al., 2017 [4] | 2nd year of infusion | 104/808 | 12,90% | I-II | NA | NA | Data from CARE-MS I and CARE-MS II. | |
Baker D et al., 2017 [4] | 2nd year of infusion | 12/808 | 1,50% | III-IV | NA | NA | Data from CARE-MS I and CARE-MS II. | |
Vakrakou. et al., 2018 [17] | 1rst year of infusion (12 mg/d) | 1 | case report | III | 9 weeks | 9 days | Prezolon (25 mg for 3 days and 12,5 mg for another 3 days) | LGL cells predominated in peripheral blood |
Galgani S et al., 2018 [6] | 1rst year of infusion (12 mg/d) | 1 | Case report | III/IV | 1 month | 2 weeks | Resolved spontaneously |